Form 4 Filing for Fulcrum Therapeutics, Inc.

This filing details transactions by TANG KEVIN and TANG CAPITAL MANAGEMENT LLC, both significant owners of Fulcrum Therapeutics, Inc. (FULC). On July 16, 2026, 116,671 shares of Common Stock were acquired at a weighted-average price of $3.56, bringing the total post-transaction shares to 7,030,000. On July 17, 2026, an additional 50,945 shares of Common Stock were acquired at a weighted-average price of $3.52, increasing the total post-transaction shares to 7,080,945. The prices reported are weighted-averages, with purchases occurring within specified ranges as detailed in the footnotes. The footnotes also clarify the intricate ownership structure involving various Tang Capital entities and Kevin Tang's beneficial interest and control.